Simple Summary Despite recent progress in the treatment of metastatic colorectal cancer
patients, novel therapeutic approaches are highly warranted to further improve outcome …

Liquid biopsies refer to the isolation and analysis of tumor-derived biological material from
body fluids, most commonly blood, in order to provide clinically valuable information for the …

Context Predictive and prognostic biomarkers in the perioperative treatment of muscle-
invasive bladder cancer (MIBC) are an unmet need. Circulating tumor DNA (ctDNA) holds …

Simple Summary Early-stage disease non-small cell lung cancer has better outcomes than
advanced disease, but 5-year survival rates can drop to approximately 50% in cases of …

Abstract Background Circulating tumour DNA (ctDNA) to detect minimal residual disease
(MRD) is emerging as a biomarker to predict recurrence in patients with curatively treated …

Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative
review - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

Background Postoperative adjuvant chemotherapy (AC) is now well-accepted as standard
for high-risk stage II and stage III colorectal cancer (CRC) patients, however the optimal time …

Immunotherapy with immune-checkpoint inhibitors (ICIs) targeting programmed cell death 1
or programmed death-ligand 1 has revolutionised the treatment of advanced non-small cell …

Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular
residual disease (MRD) detection in lung cancer. As the next‐generation sequencing …

Emerging data have suggested that circulating tumor DNA (ctDNA) can be a reliable
biomarker for minimal residual disease (MRD) in CRC patients. Recent studies have shown …